Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $182.8 million.

  • Theravance Biopharma's Total Liabilities rose 723.26% to $182.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.8 million, marking a year-over-year increase of 723.26%. This contributed to the annual value of $178.6 million for FY2024, which is 568.74% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Total Liabilities is $182.8 million, which was up 723.26% from $201.2 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Total Liabilities peaked at $748.3 million during Q1 2021, and registered a low of $165.6 million during Q4 2022.
  • Its 5-year average for Total Liabilities is $352.6 million, with a median of $178.6 million in 2024.
  • In the last 5 years, Theravance Biopharma's Total Liabilities crashed by 7678.7% in 2022 and then surged by 1951.23% in 2025.
  • Quarter analysis of 5 years shows Theravance Biopharma's Total Liabilities stood at $713.4 million in 2021, then crashed by 76.79% to $165.6 million in 2022, then grew by 2.06% to $169.0 million in 2023, then increased by 5.69% to $178.6 million in 2024, then rose by 2.33% to $182.8 million in 2025.
  • Its Total Liabilities was $182.8 million in Q3 2025, compared to $201.2 million in Q2 2025 and $177.6 million in Q1 2025.